Abstract The sodium iodide symporter (NIS) mediates the active iodide uptake in the thyroid gland as well as lactating breast tissue. Recently, we reported significant stimulation of all-trans retinoic acid (atRA)-induced NIS expression in the estrogen-receptor positive human breast cancer cell line MCF-7 by dexamethasone (Dex) in vitro and in vivo, which might offer the potential to image and treat breast cancer with radioiodine. In this study, based on its known interaction with the pregnane-X-receptor (PXR) forming a heterodimer with the retinoid-X-receptor (RXR), we examined the effect of carbamazepine (CBZ), a potent activator of PXR, on atRA-induced NIS expression and therapeutic efficacy of 131 I in MCF-7 cells. For this purpose, functional NIS expression in MCF-7 cells was examined by iodide uptake assay, quantitative real-time PCR as well as Western blot analysis, followed by investigation of 131 I cytotoxicity in vitro after incubation with CBZ (4, 25, 100 lM) in the presence of atRA (1 lM) with or without Dex (100 nM). Incubation with CBZ stimulated atRA-induced iodide accumulation up to twofold in a concentration-dependent manner, while atRA/Dex-stimulated iodide uptake was further stimulated up to 1.5-fold by additional CBZ treatment based on significantly increased NIS mRNA and protein levels. This stimulatory effect of CBZ was shown to be dependent on the PI3K-Akt pathway without involvement of mTOR. In contrast, treatment with CBZ alone had no effect on functional NIS expression. Moreover, selective cytotoxicity of 131 I was significantly increased from approximately 20% in MCF-7 cells treated with atRA alone to 50% after treatment with CBZ in the presence of atRA, which was further enhanced to 90% after combined treatment with atRA/Dex/CBZ. In conclusion, CBZ represents another potent stimulator of atRA-induced functional NIS expression resulting in an enhanced selective killing effect of 131 I in MCF-7 breast cancer cells.
Introduction
As an intrinsic plasma membrane glycoprotein, NIS mediates the active transport of iodide at the basolateral membrane of thyroid follicular cells [1, 2] and thereby plays a key role in diagnostic and therapeutic application of radioiodine in follicular cell-derived thyroid carcinomas and their metastases.
It is well known that endogenous NIS expression is not restricted to thyroid tissue, but can also be detected in a variety of nonthyroidal tissues, such as salivary and lacrimal glands, stomach, kidney, intestine and particularly mammary gland [2, 3] . In normal mammary tissue, NIS is present exclusively during gestation and lactation, mediating the active transport and secretion of iodide into the milk thereby supplying the infant with iodide for the biosynthesis of thyroid hormones that are essential for the development of the nervous system and lungs [4] . Estrogen, prolactin, and oxytocin are known stimulators of NIS expression in the lactating mammary gland [4] .
In contrast to the restriction of NIS expression to the lactating state in normal mammary gland, NIS expression has also been detected with high frequency in human breast cancer samples as well as in several transgenic breast cancer models, where functional activity of NIS was confirmed by scintigraphic imaging. These data indicate that NIS is frequently upregulated during malignant transformation in breast tissue [4] [5] [6] [7] . Mammary NIS expression offers a powerful tool for selective breast cancer therapy based upon NIS-targeted application of radioiodine that has been used for over 60 years in the diagnosis and therapy of follicular cell-derived thyroid cancer as the most effective anticancer radiotherapy available today. In view of these data, a clinical trial was performed by Nancy Carrasco's group, in which 27 women with breast cancer metastases were scanned with 99m Tc-pertechnetate or 123 I to assess functional NIS activity in their metastases after thyroidal NIS expression was down-regulated by application of T3 alone or in combination with methimazole. However, only eight tumors revealed NIS expression which resulted in radionuclide accumulation in only two of the eight metastases [8] . Similarly, Moon et al. examined 99m Tcpertechnetate accumulation and NIS mRNA expression in 25 breast tumors and found significantly increased 99m Tcpertechnetate uptake in only four tumors, while all of the 25 tumors revealed NIS mRNA expression [5] . In a recent study, positive NIS expression was demonstrated in 65% of 23 triple-negative breast cancers (estrogen-, progesteronereceptor negative and HER2/neu negative) by immunohistochemistry [6] . One patient with NIS-positive breast cancer underwent 123 I scintigraphy demonstrating a significant uptake compared to normal breast tissue. The cumulative iodide uptake of 0.00131% ID/ml, however, was not sufficient to achieve a therapeutic effect. Therefore, it is not unexpected that stimulation of functional NIS expression will be required to induce sufficiently high levels of iodide uptake in breast cancer, which is comparable to the requirement of maximal TSH stimulation for optimization of diagnostic and therapeutic application of radioiodine in thyroid cancer [6] [7] [8] .
All-trans retinoic acid (atRA) has been demonstrated to induce both NIS gene expression as well as iodide accumulation in vitro in a well-differentiated estrogen receptorpositive human breast cancer cell line (MCF-7), which has also been confirmed in mouse breast cancer models in vivo [9] [10] [11] [12] . In more recent studies, we and others have demonstrated that dexamethasone (Dex) is able to significantly enhance atRA-induced NIS expression and iodide accumulation in MCF-7 cells in vitro and in vivo [10, [13] [14] [15] .
Retinoid receptors belong to the steroid receptor superfamily and their action is mediated through two families of nuclear receptors: retinoic acid receptors (RARs), which are activated by both atRA and 9-cis-RA and retinoid X receptors (RXRs), that are activated by 9-cis-RA only. Both receptor types are expressed in MCF-7 cells. The induction of NIS expression by atRA in breast cancer cells is mediated by the retinoic acid receptor (RAR) which forms heterodimers with the retinoid X receptor (RXR) and interacts with the PI3K-pathway as shown in recent studies [10, 16, 17] . RXR is able to heterodimerize with a large number of nuclear hormone receptors including RAR, thyroid hormone receptor (TR), peroxisome proliferating activating receptor gamma (PPARc) and the pregnane-X-receptor (PXR) [18, 19] . In this context, it has been demonstrated that treatment with the PPARc ligand troglitazone significantly stimulates retinoic acid-induced NIS expression in breast cancer cells [20] , suggesting that targeting the heterodimerization partners of RXR is able to modulate NIS expression in breast cancer.
Carbamazepine, a well-known anticonvulsant drug, is known to activate PXR which forms heterodimers with RXR, thereby inducing genes involving the CYP450 family [21, 22] . Due to its known interactions with RXR, in this study we investigated the regulation of atRA-induced NIS expression by CBZ in MCF-7 cells.
Materials and methods
Cell culture and treatments MCF-7 cells were grown in MEM medium (Invitrogen Life Technologies, Inc., Karlsruhe, Germany) supplemented with 10% fetal bovine serum (PAA, Cölbe, Germany); L-glutamine and penicillin/streptomycin (GibcoBRL) at 37°C and 5% CO 2 . 24 h after plating, cells were incubated with atRA (1 lM) (Sigma, Taufkirchen, Germany), carbamazepine (CBZ) (4, 25 and 100 lM) and/or dexamethasone (Dex) (100 nM) (Sigma) in the presence of 10% charcoal-stripped fetal bovine serum for 24 h.
Iodide uptake studies Uptake of 125 I by untreated and treated MCF-7 cells was determined at steady-state conditions as described by Weiss et al. [23] . In brief, cells were plated on six-well plates (3 9 10 5 cells/well), and following incubation with atRA (1 lM), CBZ (4, 25, and 100 lM) and Dex (100 nM), respectively, iodide uptake studies were performed in Hanks' balanced salt solution (HBSS) supplemented with 10 lM NaI, 0.1 lCi Na 125 I/ml, and 10 mM HEPES (pH 7.3). In control wells, KClO 4 was added at a concentration of 100 lM. Following incubation for 1 h, trapped iodide was removed from cells by a 20-min incubation in 1 N NaOH and measured by c-counting. Results were normalized to cell survival measured by cell viability assay (see below) and expressed as cpm/A490 nm.
For signaling pathway analysis, cells were simultaneously treated with the specific PI3K inhibitor wortmannin (250 nM) (Sigma, Taufkirchen, Germany), the specific mTOR inhibitor rapamycin (20 nM) (Biozol Diagnostica, Eching, Germany) and the PI3K inhibitor Ly294002 (10 lM) (EMD Bioscience, La Jolla, CA, USA) followed by measurement of iodide uptake. As control DMSO was added to the cells at the same concentration as for the inhibitors that were diluted in DMSO.
Cell viability assay
Cell viability was measured using the commercially available MTS-assay (Promega Corp., Mannheim, Germany) according to the manufacturer's recommendations.
RNA preparation and real-time q-PCR analysis
Total RNA was isolated from untreated and treated MCF-7 cells, respectively, using the Rneasy Mini kit (Qiagen, Hilden, Germany) according to manufacturer's recommendations. Single stranded oligo (dT)-primer cDNA was generated using Superscript III Reverse Transcriptase (Invitrogen). Following primers were used: hNIS (5 0 -TGC GGGACTTTGCAGTACATT-3 0 ) and (5 0 -TGCAGATAA TTCCGGTGGACA-3 0 ), GAPDH: (5 0 -GAGAAGGCTGG GGCTCATTT-3 0 ) and (5 0 -CAGTGGGGACACGGAAGG-3 0 ). Quantitative real-time PCR (qPCR) was performed with the cDNA from 1 lg RNA using the SYBR green PCR master mix (Quiagen) in a Rotor Gene 6000 (Corbett Research, Morthlake, New South Wales, Australia). Levels of NIS cDNA were normalized to GAPDH cDNA levels. Relative expression levels were calculated using the comparative DDC t method and internal GAPDH for normalization.
Membrane preparation
Cell membranes were prepared from treated and untreated MCF-7 cells as described earlier [14] .
Western blot analysis
Western blot analysis was performed as described previously [14] .
Immunofluorescence analysis MCF-7 cells were grown on glass slides (Histobond, Medim, Gießen, Germany) to 50-60% confluency and treated as described above. After treatment cells were fixed for 5 min in 80% methanol at 4°C followed by 2 min in acetone at -20°C, rehydrated in PBS, and blocked for 15 min in PBS with 12% BSA. First, the mouse monoclonal hNIS-specific antibody directed against amino acid residues 468-643 of human NIS (dilution 1:2000 in 4% BSA/PBS) [24] (kindly provided by J.C. Morris, Division of Endocrinology, Mayo Clinic and Medical School, Rochester, MN, USA) was incubated overnight at 4°C in a moist chamber; after three washes in PBS, cells were incubated for 30 min at room temperature with mouse-specific, Cy3-conjugated secondary antibody (Dianova, Hamburg, Germany), as well as 0.5 lg/ml bisbenzimide (Hoechst No. 33258) DNA dye for nuclear counter staining. After three final washes with PBS, specimens were mounted with Mowiol (Medim, Gießen, Germany) under a coverslip and examined and photographed using a Zeiss microscope (Zeiss, Martinsried, Germany) equipped with epifluorescence optics. Parallel monolayers with the primary and secondary antibodies replaced in turn by PBS and isotype-matched nonimmune IgGs were examined to assure specificity and to exclude cross-reactivities between the antibodies and conjugates used.
In vitro clonogenic assay
The in vitro clonogenic assay was performed as described by Mandell et al. [25] . In brief, untreated and treated MCF-7 cells were grown in 75 cm 2 flasks, washed with HBSS, and incubated for 7 h with 10 ml of 80 lCi/ml Na 131 I in HBSS supplemented with 10 lM NaI and 10 mM HEPES at pH 7.3. Following incubation with radioiodine, cells were washed with HBSS, trypsinized using 0.05% trypsin-EDTA, and plated at cell densities of 250, 500, 1,000, 2,000, 3,000, and 5,000 and cells/well in 12-well plates. Two weeks later, after colony development, cells were fixed with methanol, stained with crystal violet, and colonies containing more than 50 cells were counted. Parallel experiments were performed for each treatment using HBSS without 131 I, and all values were adjusted for plating efficiency. The percentage of survival represents the percentage of cell colonies after 131 I treatment, compared with mock treatment with HBSS.
Statistical methods
All experiments were carried out in triplicates. For the clonogenic assay, ten wells were evaluated for each condition and cell density. Results are presented as means ± SD of triplicates. Statistical significance was tested using Student's t test. Results shown are representative of three experiments performed under the same conditions.
Results

CBZ stimulates atRA-induced iodide uptake activity in MCF-7 cells
The effect of CBZ (4, 25 and 100 lM) on atRA (1 lM)-induced iodide accumulation was studied in MCF-7 in the presence or absence of Dex (100 nM), as well as in control cells without atRA treatment after 24 h (Fig. 1) . While untreated cells as well as MCF-7 cells treated with CBZ and Dex alone or in combination showed no iodide uptake activity, treatment with atRA alone induced perchloratesensitive iodide uptake, which was stimulated up to twofold by the additional treatment with CBZ in a dose-dependent manner (P \ 0.01) (Fig. 1) . Further, atRA-induced iodide uptake was stimulated threefold by additional treatment with Dex in MCF-7 cells (P \ 0.01). Incubation with CBZ resulted in a further increase in iodide uptake activity up to 1.5-fold in MCF-7 cells treated with atRA and Dex. Maximal stimulation of iodide accumulation up to sixfold was seen at 100 lM CBZ in the presence of 1 lM atRA and 100 nM Dex as compared to treatment with atRA alone after 24 h (P \ 0.01) (Fig. 1) .
CBZ increases atRA-induced NIS mRNA expression
After incubation of MCF-7 cells for 24 h with CBZ (4, 25, 100 lM) in the presence or absence of atRA (1 lM) and Dex (100 nM), NIS mRNA was isolated and processed for real-time PCR after cDNA synthesis. A significant upregulation of NIS mRNA up to twofold was detected following treatment with CBZ in a dose-dependent manner in the presence of atRA (P \ 0.05). Moreover, Dex-stimulated, atRA-induced NIS mRNA expression was further enhanced up to 1.5-fold by the concomitant treatment with CBZ (P \ 0.05) (Fig. 2) .
CBZ stimulates atRA-induced NIS protein expression in MCF-7 cells
After incubation of MCF-7 cells for 24 h with CBZ (100 lM) in the presence or absence of atRA (1 lM) and Dex (100 nM), NIS protein expression levels were examined by Western blot analysis using a mouse monoclonal human NIS-specific antibody (Fig. 3) . NIS protein was detected as a band of approximately 90 kDa. Treatment with CBZ in the presence of atRA increased NIS protein levels up to threefold. atRA-induced NIS expression was increased approximately eightfold by additional treatment with Dex, while NIS protein expression was further stimulated 9.7-fold by combined treatment with atRA, Dex, and CBZ as compared to cells treated with atRA alone (1 lM). No NIS protein expression was detected in untreated MCF-7 cells. The additional band that migrates above the 75 kDa molecular weight marker and that is present in untreated as well as treated cells represents a nonspecific band. To determine whether stimulation of atRA-induced functional NIS expression by CBZ is dependent on the PI3K pathway in MCF-7 cells, we treated the cells with inhibitors of PI3K (Ly294002; wortmannin) [26] . While incubation with wortmannin or Ly294002 resulted in a 35-40% reduction of accumulated iodide in atRA-treated MCF-7 cells, cells incubated with atRA and CBZ or atRA/Dex and CBZ showed a reduction in iodide uptake activity of approximately 60 and 70%, respectively (Fig. 4a) . In addition, we treated the cells with the specific mTOR inhibitor rapamycin, which did not result in a significant decrease in iodide uptake activity in cells incubated with atRA and CBZ or atRA/Dex and CBZ (Fig 4a) . Therefore, it can be concluded that stimulation of atRA-induced NIS expression by CBZ is mediated via the PI3K-Akt pathway without involvement of mTOR. Moreover, inhibition of PI3K by wortmannin and Ly294002 resulted in a significant reduction in NIS protein expression, while inhibition of mTOR by rapamycin did not significantly affect NIS protein expression in MCF-7 cells treated with atRA and CBZ or atRA/Dex and CBZ (Fig 4b) .
Confirmation of NIS protein expression by immunocytochemical staining
Using immunofluorescence staining NIS expression was analyzed following stimulation of atRA-induced (1 lM) (Fig. 5a) , frequency of NIS expressing cells is clearly increased after simultaneous incubation with CBZ (Fig. 5b) . After combined treatment with atRA, Dex, and CBZ not only frequency but also intensity of NIS-specific staining is significantly enhanced (Fig. 5c ). To determine the effect of CBZ (100 lM) on atRA (1 lM) treatment with or without Dex (100 nM) on cytotoxicity of 131 I in vitro in MCF-7 cells a clonogenic assay was performed (Fig. 6) . No cell killing was observed in untreated cells after exposure to 131 I, and no significant change of cytotoxicity was observed after treatment with CBZ or Dex alone or with combined treatment with CBZ and Dex. In contrast, approximately 20% of MCF-7 cells incubated for 24 h with 1 lM atRA alone were killed by 131 I in an in vitro clonogenic assay. After additional treatment with CBZ for 24 h in the presence of atRA, this cytotoxic effect of 131 I was increased to approximately 50% (P \ 0.001). In addition, after combined treatment with atRA, Dex, and CBZ, the cytotoxic effect of 131 I was elevated to 90% as compared to 80% using atRA and Dex alone (P \ 0.001) (Fig. 6a) . Further, in the control group (without 131 I) of the in vitro clonogenic assay, we observed no significant effect of atRA, Dex or CBZ on MCF-7 cell proliferation (Fig. 6b) .
Discussion
The aim of this study was to examine the regulation of atRA-induced sodium iodide symporter (NIS) expression in the estrogen-receptor positive human breast cancer cell line MCF-7 by carbamazepine (CBZ) in the presence or absence of dexamethasone (Dex). Treatment with CBZ significantly increased atRA-induced NIS mRNA and protein levels as well as iodide accumulating activity, which was further increased after combined treatment with CBZ and Dex, and resulted in significantly increased selective killing effect of 131 I in MCF-7 cells in vitro. In the thyroid gland, NIS-mediated iodide accumulation is not only the first and rate-limiting step in the process of thyroid hormone synthesis, but also allows the application of radioiodine for diagnostic evaluation of thyroid nodules by thyroid scintigraphy, as well as ablation of postsurgical remnants and treatment of recurrent and metastatic disease in thyroid cancer. Diagnostic and therapeutic application of radioiodine which is based on selective NIS-mediated radionuclide transport is therefore one of the oldest and most successful examples of molecularly targeted imaging and therapy.
Iodide accumulation in breast tissue was first reported more than 50 years ago [27] , and was later discovered to be mediated by expression of NIS in mammary gland during lactation and in malignant disease [2, 4] . In subsequent studies, it was demonstrated that NIS is frequently expressed during malignant transformation of mammary epithelial cells. Various groups have demonstrated that high levels of NIS protein expression in human samples of mammary cancers with high frequency [4] [5] [6] [7] [8] .
The high prevalence of NIS in human breast cancer and the demonstration of functionally active NIS expression in transgenic breast cancer mouse models such as the MMTVPyVT, Ubi-hCGß, and MMTV-neu model, suggest that endogenous mammary NIS expression may offer the possibility of NIS-targeted radioiodine imaging and therapy in breast cancer similar to its application in thyroid cancer [6] [7] [8] 28 ]. However, currently available studies [5, 6, 8] suggest that stimulation of mammary NIS expression will be necessary to maximize diagnostic and therapeutic efficacy of NIS-mediated radioiodide accumulation in breast cancer, similar to TSH stimulation of thyroidal NIS, that is required for maximizing sensitivity and efficiency of radioiodine application in diagnosis and therapy of thyroid cancer. Kogai et al. were the first to report increased functional NIS expression in the human breast cancer cell line MCF-7 in vitro after administration of retinoic acid and various retinoid receptor ligands, including 9-cis retinoic acid, AGN190168, a RAR b/c-agonist, as well as atRA. In addition, significant induction of NIS mRNA and protein expression and markedly increased iodide accumulation was demonstrated in vivo in xenograft tumors after atRA treatment [9] [10] [11] . Based on those studies, we and others demonstrated a stimulatory effect on atRA-induced NIS expression in MCF-7 cells by the addition of glucocortiocoids [10, 13, 14] . In addition to stabilization of NIS mRNA by glucocorticoids, it has been suggested that the increased iodide accumulation in MCF-7 cells after stimulation with atRA and Dex might be mediated by Dexpotentiated RAR/RXR heterodimerization, and therefore increased ligand-dependent transcription of the NIS gene [10, 13, 14] . However, the exact mechanism by which atRA-induced NIS expression is stimulated by glucocorticoids need to be addressed in further studies. Moreover, we were able to confirm these results in vivo in MCF-7 xenotransplants, which accumulated approx. 3-5% of the injected dose 123 I per gram tumor (% ID/g) after systemic atRA and Dex treatment as shown by gamma camera imaging [15] . However, although a significant iodide uptake activity was induced by atRA and Dex in vivo, an additional stimulation of NIS expression is desirable to enhance sensitivity and efficacy of diagnostic and therapeutic application of radioiodine in breast cancer.
In this current study, atRA-induced iodide accumulation was significantly enhanced by the addition of CBZ, while CBZ alone did not result in induction of functional NIS expression. In addition, atRA-induced and Dex-stimulated functional NIS expression was further enhanced by additional treatment with CBZ. Stimulation of functional NIS expression in atRA-and atRA/Dex-treated MCF-7 cells by CBZ was confirmed on mRNA and protein levels using real-time RT-PCR, Western blot, and immunofluorescence analysis, respectively. Further, stimulation of iodide accumulation by CBZ resulted in a significantly increased therapeutic effect of 131 I as shown in an in vitro clonogenic assay. These data suggest that the enhanced therapeutic effect of 131 I after treatment with CBZ and atRA with or without additional Dex treatment was due to stimulation of iodide accumulation based on increased NIS mRNA and protein expression.
Carbamazepine (CBZ) is a well-known anticonvulsant and a potent inducer of a broad spectrum of drug-metabolizing enzymes, including CYP3A4, perhaps the most important drug-metabolizing enzyme. The induction of CYP3A4 by CBZ is mediated via activation of the PXR, a nuclear orphan receptor, which is mainly expressed in the liver and intestine. Moreover, PXR expression was also demonstrated in a variety of other tissues including human breast cancers [19, 29] . Further, it has been shown that PXR is expressed in human mammary carcinoma cell lines, such as MCF-7 and MDA-MB-231 [29] . PXR is known to form heterodimers with RXR, thereby inducing a large number of genes involved in xenobiotic metabolism, including oxidation, conjugation and transport [19, 22] . Furthermore, PXR-RXR heterodimers bind to DR-3, ER-6, ER-8, DR-4 and DR-5 response elements in many genes [30] . Since a DR-5 response element was identified in the human NIS gene, it is possible that PXR-RXR heterodimers act via the DR-5 response element thereby enhancing atRA-induced NIS expression in MCF-7 cells [16] .
In our study, inhibition of PI3K by either wortmannin or Ly294992 resulted in a significant decrease of atRAinduced and CBZ-stimulated iodide uptake activity, while inhibition of mTOR by rapamycin did not affect functional NIS expression, suggesting that activation of the PI3K-Akt pathway but not mTOR is essential for the stimulation of atRA-induced NIS expression by CBZ in MCF-7 cells. These data are consistent with a study by Kogai et al., demonstrating that treatment with Ly294002 but not rapamycin decreases atRA-induced iodide uptake activity in MCF-7 cells [16] . Moreover, these data confirm a recently published study by Ohashi et al. showing that PI3K mediates induction of functional NIS expression by retinoic acid in MCF-7 cells [17] . Although selective RXR agonists fail to induce NIS expression, as shown in the same study, specific inhibition of RXR by Hx531 resulted in significant decrease in atRA-induced functional NIS expression suggesting that heterodimerization of RAR and RXR is essential for atRA-mediated NIS induction in MCF-7 cells [17] . In consideration of these data, it might be possible that stimulation of atRA-induced NIS expression by CBZ acts via PXR-RXR thereby stimulating RXR-RAR heterodimerization. However, the exact mechanism by which CBZ stimulates atRA-induced NIS expression in MCF-7 cells is currently not fully understood and will be addressed in future studies.
In conclusion, treatment with CBZ in addition to atRA or atRA/Dex increases functional NIS expression levels, thereby significantly enhancing iodide accumulation and the selective killing effect of 131 I in MCF-7 cells. Therefore, based on the extensive experience with radioiodine in diagnosis and therapy of thyroid cancer, treatment with CBZ, atRA and Dex may allow diagnostic and therapeutic application of radioiodine in breast cancer in the future. Due to the induction of a broad spectrum of drug-metabolizing enzymes, possible interactions with concomitant breast cancer medication will have to be taken into account.
